LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Search

CRISPR Therapeutics AG

Fechado

SetorSaúde

55.1 -2.8

Visão Geral

Variação de preço das ações

24h

Atual

Mín

54.86

Máximo

58.01

Indicadores-chave

By Trading Economics

Rendimento

-24M

-131M

Vendas

-25K

864K

Margem de lucro

-15,117.245

Funcionários

393

EBITDA

-48M

-149M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+30.07% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

445M

5.2B

Abertura anterior

57.9

Fecho anterior

55.1

Sentimento de Notícias

By Acuity

25%

75%

71 / 351 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

CRISPR Therapeutics AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de fev. de 2026, 23:25 UTC

Ações em Alta

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 de fev. de 2026, 23:15 UTC

Ganhos

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 de fev. de 2026, 23:54 UTC

Conversa de Mercado

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 de fev. de 2026, 23:47 UTC

Ganhos

Ferrovial 4Q Net EUR197M >FER.MC

25 de fev. de 2026, 23:45 UTC

Ganhos

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 de fev. de 2026, 23:42 UTC

Ganhos

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 de fev. de 2026, 23:38 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Company's Business Operations Remain Normal >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com FY EPS CNY47.67 >TCOM

25 de fev. de 2026, 23:06 UTC

Ganhos

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 de fev. de 2026, 23:01 UTC

Ganhos

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 de fev. de 2026, 23:00 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

25 de fev. de 2026, 23:00 UTC

Conversa de Mercado
Ganhos

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 de fev. de 2026, 22:56 UTC

Conversa de Mercado
Ganhos

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 de fev. de 2026, 22:43 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 de fev. de 2026, 22:40 UTC

Conversa de Mercado
Ganhos

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 de fev. de 2026, 22:40 UTC

Ganhos

Karoon Energy Says Search for New CFO Well Advanced

25 de fev. de 2026, 22:39 UTC

Ganhos

Karoon Energy Says CFO Ray Church to Leave Company

25 de fev. de 2026, 22:39 UTC

Ganhos

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 de fev. de 2026, 22:38 UTC

Ganhos

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Comparação entre Pares

Variação de preço

CRISPR Therapeutics AG Previsão

Preço-alvo

By TipRanks

30.07% parte superior

Previsão para 12 meses

Média 70.21 USD  30.07%

Máximo 105 USD

Mínimo 33 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para CRISPR Therapeutics AG - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

15 ratings

10

Comprar

4

Manter

1

Vender

Pontuação Técnica

By Trading Central

33.5 / 38.27Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

71 / 351 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat